Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals Inc (EGRX) Q2 2019 Earnings Call Transcript
Aug. 9, 2019 | Price: Free! | Source: Motley Fool

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2019 Results - Earnings Call Transcript
Aug. 9, 2019 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2019 Results - Earnings Call Transcript
May 7, 2019 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2018 Results - Earnings Call Transcript
Feb. 28, 2019 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals Inc. (EGRX) CEO Scott Tarriff on Q3 2018 Results - Earnings Call Transcript
Nov. 1, 2018 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals Inc. (EGRX) CEO Scott Tarriff on Q2 2018 Results - Earnings Call Transcript
Aug. 7, 2018 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2018 Results - Earnings Call Transcript
May 10, 2018 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2017 Results - Earnings Call Transcript
Feb. 26, 2018 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q3 2017 Results - Earnings Call Transcript
Nov. 8, 2017 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q2 2017 Results - Earnings Call Transcript
Aug. 9, 2017 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2017 Results - Earnings Call Transcript
May 8, 2017 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2016 Results - Earnings Call Transcript
March 1, 2017 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q3 2016 Results - Earnings Call Transcript
Nov. 9, 2016 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q2 2016 Results - Earnings Call Transcript
Aug. 9, 2016 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2016 Results - Earnings Call Transcript
May 9, 2016 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2015 Results - Earnings Call Transcript
Feb. 25, 2016 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q3 2015 Results - Earnings Call Transcript
Nov. 11, 2015 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q2 2015 Results - Earnings Call Transcript
Aug. 11, 2015 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2015 Results - Earnings Call Transcript
May 18, 2015 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2014 Results - Earnings Call Transcript
Dec. 17, 2014 | Price: Free! | Source: Seeking Alpha

Recent filings

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - Aug. 8, 2019

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results - Aug. 8, 2019

Eagle Pharmaceuticals Announces Clinical Development Plan Of Innovative Product Intended To Deliver Maximum Estrogen Receptor Inhibition In Patients With Estrogen Receptor (Er)-Positive Breast Cancer - Aug. 5, 2019

Submission of Matters to a Vote of Security - June 21, 2019

Eagle Pharmaceuticals June 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved - June 4, 2019

Eagle Pharmaceuticals May 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved 1 - May 22, 2019

Douglas L. Braunstein just provided an update on activist position in Eagle Pharmaceuticals - May 14, 2019

Eagle Pharmaceuticals director just disposed of 159,223 shares - May 13, 2019

Eagle Pharmaceuticals May 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved 1 - May 8, 2019

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - May 7, 2019

Eagle Pharmaceuticals Announces Positive Results Of A Study Conducted In Partnership With The U.S. Military To Evaluate Neuroprotective Effects Of Ryanodex For The Treatment Of Nerve Agent Exposure - May 7, 2019

Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results - May 7, 2019

Other definitive proxy statements - April 30, 2019

Eagle: Soliciting Material Under §240.14A-12 Eagle Pharmaceuticals, Inc. - April 30, 2019

Eagle Pharmaceuticals, Inc. Expands Licensing Agreement For Bendeka™ With Teva Pharmaceuticals International Gmbh - April 15, 2019

Major owner of Eagle Pharmaceuticals just disposed of 24,975 shares - April 3, 2019

Eagle Pharmaceuticals director just picked up 2,340 shares - March 6, 2019

Eagle Pharmaceuticals director just picked up 2,136 shares - March 6, 2019

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2018 Results - Feb. 28, 2019

Eagle Pharmaceuticals Just Filed Its Annual Report: Earnings Per ShareBa... - Feb. 28, 2019

Eagle Pharmaceuticals February 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved 1 - Feb. 21, 2019

Michael Graves just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 14, 2019

Peter S. Park just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 14, 2019

STATE STREET CORPORATION just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 14, 2019

Janus Henderson Group plc EIN just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 12, 2019

Major owner of Eagle Pharmaceuticals just disposed of 30,085 shares - Feb. 4, 2019

Victory Capital Management Inc. just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 1, 2019

BlackRock, Inc. just provided an update on share ownership of Eagle Pharmaceuticals - Jan. 28, 2019

Eagle Pharmaceuticals's EVP and Chief Medical Officer just picked up 18,229 shares - Jan. 25, 2019

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 25, 2019

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 25, 2019

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 25, 2019

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 25, 2019

Major owner of Eagle Pharmaceuticals just picked up 61,300 shares - Jan. 25, 2019

Eagle Pharmaceuticals's Chief Financial Officer just picked up 18,700 shares - Jan. 25, 2019

Eagle Pharmaceuticals's Pres. & Chief Comm. Officer just picked up 20,042 shares - Jan. 25, 2019

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 25, 2019

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 25, 2019

Eagle Pharmaceuticals January 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved 1 - Jan. 7, 2019

Major owner of Eagle Pharmaceuticals just disposed of 31,569 shares - Jan. 4, 2019

Securities to be offered to employees in employee benefit plans - Dec. 18, 2018

Eagle Pharmaceuticals Announces Positive Results Of Pre-Clinical Study Conducted To Evaluate Effects Of Ryanodex In Acute Radiation Syndrome (Ars) - Nov. 27, 2018

Eagle Pharmaceuticals November 2018 Confidential © 2018 Eagle Pharmaceuticals, Inc. All Rights Reserved - Nov. 8, 2018

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results - Nov. 1, 2018

Eagle Pharmaceuticals Announces Results Of Study For Fulvestrant - Oct. 30, 2018

Eagle Pharmaceuticals Commences $50 Million Accelerated Share Repurchase As Part Of New $150 Million Share Repurchase Authorization - Oct. 30, 2018

Eagle Pharmaceuticals October 2018 - Oct. 3, 2018

Eagle Pharmaceuticals Enters Into Agreement With Usamricd To Evaluate Neuroprotective Effects Of Ryanodex Secondary To Nerve Agent Exposure - Oct. 3, 2018

Departure of Directors or Certain - Sept. 26, 2018

Eagle Pharmaceuticals September 2018 - Sept. 13, 2018

Eagle Pharmaceuticals Concludes Enrollment Of Second Safety And Efficacy Study At Hajj To Evaluate Ryanodex For Exertional Heat Stroke - Aug. 30, 2018

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - Aug. 7, 2018

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results - Aug. 7, 2018

Fda Grants Eagle Seven Year Orphan Drug Exclusivity For Bendeka (Bendamustine Hydrochloride Injection) WOODCLIFF LAKE, N.J. - July 9, 2018

Submission of Matters to a Vote of Security - June 22, 2018

Court Issues Decision In Favor Of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity For - June 11, 2018

Eagle Pharmaceuticals, Inc. Granted Final Fda Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In A 500Ml Admixture - May 16, 2018

Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results - May 10, 2018

Eagle: Soliciting Material Under §240.14A-12 Eagle Pharmaceuticals, Inc. - April 30, 2018

Other definitive proxy statements - April 30, 2018

Eagle Pharmaceuticals’ Vasopressin Anda Accepted For Filing By The Fda - April 16, 2018

Eagle Pharmaceuticals Announces New Patent For Eagle Biologics - March 28, 2018

Eagle Pharmaceuticals March 2018 - March 20, 2018

Eagle Pharmaceuticals March 2018 - March 7, 2018

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2017 Results - Feb. 26, 2018

Departure of Directors or Certain - Feb. 22, 2018

Eagle Pharmaceuticals February 2018 - Feb. 21, 2018

Michael Graves just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 14, 2018

Peter S. Park just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 14, 2018

Janus Henderson Group plc EIN just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 12, 2018

Victory Capital Management Inc. just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 7, 2018

Departure of Directors or Certain - Jan. 30, 2018

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 9, 2018

Eagle Pharmaceuticals's EVP & Chief Scientific Officer just picked up 3,000 shares - Jan. 9, 2018

Eagle Pharmaceuticals's Pres. & Chief Comm. Officer just picked up 10,000 shares - Jan. 9, 2018

Eagle Pharmaceuticals's Chief Financial Officer just picked up 7,000 shares - Jan. 9, 2018

Eagle Pharmaceuticals's CEO was just granted 346,000 options and restricted shares - Jan. 9, 2018

Eagle Pharmaceuticals's EVP and Chief Medical Officer just picked up 9,000 shares - Jan. 9, 2018

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 9, 2018

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 9, 2018

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 9, 2018

Departure of Directors or Certain - Jan. 9, 2018

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 9, 2018

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 9, 2018

. Iridian Asset Management LLC just provided an update on share ownership of Eagle Pharmaceuticals - Jan. 8, 2018

Eagle Pharmaceuticals January 2018 - Jan. 8, 2018

. Iridian Asset Management LLC just provided an update on share ownership of Eagle Pharmaceuticals - Jan. 8, 2018

Confidential treatment order - Dec. 22, 2017

Eagle Pharmaceuticals director just picked up 2,340 shares - Dec. 20, 2017

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results - Nov. 8, 2017

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - Nov. 8, 2017

Eagle Pharmaceuticals Receives Tentative Fda Approval For Pemfexy (Pemetrexed Injection) Ready-To-Dilute - Oct. 27, 2017

Eagle Pharmaceuticals September 2017 - Sept. 26, 2017

Eagle Pharmaceuticals Licenses Japanese Rights For - Sept. 20, 2017

Eagle Pharmaceuticals September 2017 - Sept. 13, 2017

Peter S. Park just provided an update on share ownership of Eagle Pharmaceuticals - Aug. 24, 2017

Eagle Pharmaceuticals's Chief Financial Officer just picked up 350 shares - Aug. 16, 2017

Eagle Pharmaceuticals director just picked up 20,400 shares - Aug. 11, 2017

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results - Aug. 9, 2017

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - Aug. 9, 2017

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. ProQuest Associates IV LLC 3,652,284 0.9 June 30, 2017
2. JANUS CAPITAL MANAGEMENT LLC 1,454,778 0.1 March 31, 2017
3. Park West Asset Management LLC 1,300,000 2.7 June 30, 2019
4. Peter S. Park 1,260,611 N/A April 5, 2016
5. Hudson Executive Capital LP 811,777 4.4 June 30, 2019
6. BlackRock Fund Advisors 769,869 N/A Sept. 30, 2016
7. VANGUARD GROUP INC 753,474 N/A June 30, 2019
8. State Street Corp 656,136 N/A June 30, 2019
9. LSV ASSET MANAGEMENT 404,369 N/A June 30, 2019
10. Invesco Ltd. 402,792 N/A June 30, 2019
11. Invesco Ltd. 402,792 N/A June 30, 2019
12. DIMENSIONAL FUND ADVISORS LP 248,048 N/A June 30, 2019
13. BlackRock Institutional Trust Company, N.A. 221,266 N/A Dec. 31, 2016
14. Matarin Capital Management, LLC 202,652 0.8 June 30, 2019
15. MORGAN STANLEY 190,911 N/A Sept. 30, 2017
16. MORGAN STANLEY 190,911 N/A Sept. 30, 2017
17. AJO, LP 188,368 0.1 June 30, 2019
18. MORGAN STANLEY 172,183 N/A Dec. 31, 2016
19. MORGAN STANLEY 166,956 N/A June 30, 2018
20. MORGAN STANLEY 166,956 N/A June 30, 2018
21. MORGAN STANLEY 166,857 N/A Dec. 31, 2017
22. NORTHERN TRUST CORP 165,554 N/A June 30, 2018
23. NORTHERN TRUST CORP 164,571 N/A June 30, 2018
24. NORTHERN TRUST CORP 164,571 N/A June 30, 2018
25. SUSQUEHANNA INTERNATIONAL GROUP, LLP 162,703 N/A June 30, 2019
26. SUSQUEHANNA INTERNATIONAL GROUP, LLP 162,703 N/A June 30, 2019
27. SUSQUEHANNA INTERNATIONAL GROUP, LLP 157,890 N/A June 30, 2019
28. GEODE CAPITAL MANAGEMENT, LLC 156,788 N/A June 30, 2019
29. Smith, Graham & Co., Investment Advisors, LP 153,674 0.9 June 30, 2019
30. NORGES BANK 149,808 N/A June 30, 2018

Eagle Pharmaceuticals (EGRX)

140
 


Feedback